{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-029634","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2025-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.559249+00:00","generated_at":"2026-05-16T12:03:28.359081+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncotelic closes initial $800K convertible note offering at 12% with warrants","bullets":["Issued 32 units at $25,000 each to 21 accredited investors; total $800,000 raised.","Each unit consists of a 2-year 12% note convertible into Oncotelic stock at $0.10/share or EdgePoint AI stock at $1.00/share.","Each unit also includes warrants to buy 250,000 Oncotelic shares at $0.12 or 25,000 EdgePoint warrants at $1.25.","Offering allows up to 500 units ($12.5M); prior 2023 PPM note exchanged as part of deal.","Registration rights granted for shares issuable under the units and warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-029634","json":"https://secwatch.observer/filing/0001493152-25-029634.json","markdown":"https://secwatch.observer/filing/0001493152-25-029634.md","text":"https://secwatch.observer/filing/0001493152-25-029634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315225029634/0001493152-25-029634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315225029634/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:03:28.359081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}